Yahoo
Tokyo - Delayed Quote JPY

Daito Pharmaceutical Co., Ltd. (4577.T)

1,371.00 -11.00 (-0.80%)
At close: October 16 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 4577.T
  • Previous Close 1,382.00
  • Open 1,380.00
  • Bid 1,371.00 x --
  • Ask 1,373.00 x --
  • Day's Range 1,365.00 - 1,396.00
  • 52 Week Range 1,120.00 - 1,521.00
  • Volume 103,300
  • Avg. Volume 70,250
  • Market Cap (intraday) 38.744B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 12.99
  • EPS (TTM) 105.55
  • Earnings Date (est.) --
  • Forward Dividend & Yield 45.00 (3.26%)
  • Ex-Dividend Date Nov 27, 2026
  • 1y Target Est 1,390.00

Daito Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients (APIs) for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company also engages in wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. Daito Pharmaceutical Co., Ltd. was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co., Ltd. in 1992. Daito Pharmaceutical Co., Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.

www.daitonet.co.jp

1,085

Full Time Employees

May 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/16/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4577.T
2.79%
Nikkei 225 (^N225)
29.77%

1-Year Return

4577.T
14.81%
Nikkei 225 (^N225)
35.31%

3-Year Return

4577.T
56.11%
Nikkei 225 (^N225)
106.34%

5-Year Return

4577.T
5.05%
Nikkei 225 (^N225)
124.72%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 11.89B
Earnings 700M
Profit Margin 5.89%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
5B
10B
5.0%
6.0%
7.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

1,390.00
1,390.00 Average
1,371.00 Current
1,390.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/18/2026
  • Market Cap

    37.67B

  • Enterprise Value

    46.01B

  • Trailing P/E

    12.40

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.77

  • Price/Book (mrq)

    0.71

  • Enterprise Value/Revenue

    0.91

  • Enterprise Value/EBITDA

    5.36

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.39%

  • Return on Assets (ttm)

    2.78%

  • Return on Equity (ttm)

    6.07%

  • Revenue (ttm)

    49.53B

  • Net Income Avi to Common (ttm)

    3.16B

  • Diluted EPS (ttm)

    105.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.69B

  • Total Debt/Equity (mrq)

    16.09%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: